A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)
Completed · Phase 1
Conditions studied: Cystic Fibrosis
In brief
The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA.
Key facts
- Study ID
- NCT06299709
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 34
- Starts
- 2024-03-13
- Expected to finish
- 2024-05-23
- Last updated by the study team
- 2025-09-26
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion, Inc. — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.